HORIZON-PFT (Pivotal Fracture Trial) will study the effect of zoledronic acid, given once per
year, on the treatment of osteoporosis in women past menopause. Hip and vertebral fractures
are the most devastating consequences of osteoporosis. HORIZON-PFT is designed to determine
the benefits of zoledronic acid in fracture reduction at both the hip and spine.